Ending drug trial secrecy is a boon for R&D, says EU agency

Europe's medicines regulator has come out fighting for greater transparency for clinical trials, arguing that its controversial policy to end data secrecy will be "a boon to drug developers".

The strong defence of greater openness by the boss of the European Medicines Agency (EMA) and colleagues comes as the agency battles a lawsuit from two U.S. drugmakers over its plans to release data on their medicines.

• Primary Source

ESO: Background information: European Medicines Agency releases for public consultation its draft policy on the publication and access to clinical-trial data http://www.europeansources.info/record/press-release-european-medicines-agency-releases-for-public-consultation-its-draft-policy-on-the-publication-and-access-to-clinical-trial-data/

EMA: News, 22.10.13: How access to full clinical-trial data sets will benefit medicines developers http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2013/10/news_detail_001926.jsp&mid=WC0b01ac058004d5c1

EMA: Press Release: EMA/690893/2013 (13.11.13): European Medicines Agency updates on development of its policy on publication and access to clinical-trial data http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2013/11/news_detail_001954.jsp&mid=WC0b01ac058004d5c1

---